Trial Profile
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Registrational
- Acronyms PRONOUNCE
- Sponsors Ferring Pharmaceuticals
- 22 Jul 2022 This trial has been completed in France and Slovakia(End date:2021-03-29), according to European Clinical Trials Database record.
- 30 Oct 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 30 Aug 2021 Status changed from completed to discontinued, according to results published in the Circulation.